Biobot Analytics
Biobot Analytics is a wastewater intelligence platform for public health and life sciences.
Analyst Perspective
Biobot Analytics is a US health data and analytics company focused on wastewater intelligence. Its core offering is a proprietary platform and dataset that converts wastewater sampling into population-level insights on pathogens, substances, and genomic indicators, delivered through dashboards, exports, and APIs. The company serves public health agencies, government bodies, healthcare systems, and pharmaceutical or life sciences organisations that need early detection, forecasting, and geographically granular health monitoring. The business generates revenue through contract-based SaaS access, data licensing, and enterprise or government agreements tied to surveillance coverage, sampling cadence, and access levels. Its value proposition is based on privacy-preserving, aggregated health intelligence derived from wastewater rather than individual patient data, which positions it as an infrastructure layer for public health surveillance, clinical trial planning, and health-related commercial analysis.
Analyst Signal Briefing
No strategic news signals detected in the last 90 days.
Explorer Tier
Start exploring for free
Start with public company intelligence. Save companies, build your first watchlist, and unlock deeper strategic insights when you are ready.
- View public Company Profiles
- Save/watch companies
- Build your first Watchlist
- Access additional market signals
Key insights about Biobot Analytics
Category Differentiation
Biobot Analytics is not an adtech, martech, or consumer analytics company. It is a B2B health intelligence provider using wastewater data for public health and life sciences decision-making.
Biobot Analytics: About
Biobot Analytics operates a B2B software-and-data model. It collects and models wastewater-derived biological signals, packages the resulting intelligence into software platforms and licensed datasets, and sells access to public-sector and enterprise customers. Value is created through proprietary data collection and analytics, with customers using the outputs for surveillance, forecasting, operational planning, research, and clinical trial optimisation.
How Biobot Analytics Works & Monetises
Business model analysis and core revenue streams
Biobot Analytics monetises through recurring SaaS subscriptions, proprietary data licensing, and contract-based government or enterprise agreements. Commercial terms appear to be negotiated rather than openly listed, with pricing likely influenced by geographic coverage, sampling frequency, API or dashboard access, and the scope of data delivered. Public-sector customers appear to buy surveillance access and data feeds, while life sciences customers buy premium analytics, forecasting, and dataset access for research and clinical operations.
Revenue Channels
Products & Services in Categories
Verified structural categorizations from the graph
Biobot Analytics: Frequently Asked Questions
What is Biobot Analytics?
Biobot Analytics is a US company that turns wastewater sampling data into population-level health intelligence delivered through software platforms, datasets, and APIs.
Who uses Biobot Analytics?
Its paying customers include public health agencies, government bodies, healthcare systems, pharmaceutical companies, clinical trial teams, and research organisations.
How does Biobot Analytics make money?
It earns revenue from SaaS subscriptions, licensed datasets, API access, and contract-based government or enterprise agreements.
Company Facts
- Founded
- 2017
- Headquarters
- 501 Massachusetts Ave, Cambridge, MA 02139, United States
- Core Segment
- Data Provider / Broker
- Company Size
- 10–49
- Official Link
- biobot.io
